focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
….mmmm…..
I bought more Scancell today in part because of what happened to another stock I hold yesterday. As a result of another company doing a deal in the same “space” on Monday, the share price literally doubled on Tuesday. Very small and speculative stock of course, but the point is that even news which is not company-specific can move the market quickly.
I also notice that BiotechTV is sponsored by NASDAQ, amongst others, and carries an interview with a VC who pointed out that London listings materially undervalue biotech companies. I would be unsurprised if he broached that topic with Lindy. Soon see……
Ray,
“ but good news for those who have faith in the science and see it as a buying opportunity.”
Since when has ANY investor wanted a stagnant or declining share price. I want this to up, up, UP. And while the SP is falling I certainly won’t be buying more.
Lots of wishful word salad no commercialisation and since money talks and the rest walks IMO SP will continue to slide to the next fund raising.
I think the deal Lindy wants is on immunobody as a whole, judging by what she said in the 2022 AGM.
So, assuming the SCOPE trial continues to produce results well beyond those produced by the 2 CIs alone (around 50% ORR), it may be well be possible. How such a deal would be structured is anyone's guess and, of course, it takes two to make a deal.
She probably wants to wait until iSCIB1 results are released, since this has the long patent life. So, for SHs, this means a wait until at least the 4th quarter this year and probably beyond this for a possible deal.
Inevitably, if no further glymab deals are done in the meantime, the SP is likely to decline slowly. Bad news for those wanting a quick return this year, but good news for those who have faith in the science and see it as a buying opportunity. However, we may see stunning results for the SCIB1 + 2CIs cohort in Q3. This should re-ignite the interest in SCLP.
Ruck Ditto
Chelsea, I have some sympathy with Lofas stance.
I too have “written this off” emotionally. Not that because I think this is “toast” but IF the worst were to happen I wouldn’t be emotionally or financially wrecked.
Loafas - are you suggesting this is now toast?
IMO I don't think a deal would get shareholder (including Vulpes) approval under $1, there's too much potential value to settle for that where we are currently and trials in progress. On the next significant positive news I feel $2-$3 for an overall TO is possible. However, even though I'd like the TO deal myself to finally get a full exit, I'm not sure, with the various avenues of development that is likely and think the buyout/licensing of molecules and or platforms is the preferred route for the BOD. Anyway GLA
Don’t tell me what to do. I have written this investment off.
I’d suggest we’re all surprised but news has to appear at some point…
Just for interest, I haven’t “waited ten years” and I won’t be “waiting another ten years” either. I invested in 2020, shortly before Redmile, and have a similar average cost (albeit without the convertible carry).
I’m surprised that the market seems to be underwhelmed by the opportunity here…..but have little doubt that can be corrected very quickly indeed.
Lofas,
If in you opinion, the share price is going to nothing then why don't you sell up? Yet you say you'll continue to hold? Great logic right there!
11/13 if that was significant the share price would reflect that and not be on its way to nothing.
Derisory? Well in their opinion. 11/13 excellent but not statistically significant otherwise TO would have happened already. If you want to invest and wait another 10 years filled with posters and yesterdays new, be my guest.
What would Vulpes say about a share price that is half the share price that, 12 months ago, they called derisory?
What if the reason for lack of news is a bid for the whole company?
What price would Vulpes and Redmile be content to sell at? None of us know. But my guess would be a big multiple of the current share price. An agreed deal at around 60p is not an impossibility, given sector precedent and valuations.
So we know that 11 out of 13 patients on SCOPE trial have had a positive response. I would say those patients have had very good news from Scancell!!!
Try harder Lofas.
Thanks,
IMO, it is not a great price for newbies. Personally I will not add one cent to what I have, as I mentioned before I hope patients gets good news from the one of the big players in the field, I doubt it will come from SC , if it does ….great.
"It is a great price for newbies though"
Why is it? The SP has fallen from every single "great price" called out on these boards - from 33p and down. Was 5p a great price 12 years ago? Not if you have held - doubling your money in 12 years is not an exceptionally good return. Of course, if you bought at 5p 12 years ago and sold in the 30p+ range (where it sat for three years) it was a good buy.
I stand corrected Lofas, apologies. It is hugely frustrating for us LTH's I agree, however just in my opinion, in the grand scheme of things whether the price is 9p, 10p, 11p, 12p, even 15p is somewhat irrelevant.
It is a great price for newbies though, which is no comfort for us LTH's though.
I’d say 20.02 is a bit early to be hitting the bottle - or discussion boards.
If there is a BOD, they are FAST asleep!!!!!
Obviously, you are very happy , lots of reasons to be, not point to be upset, what good it will bring, wrote off this investment not selling and equally not adding more.
Do I get the impression that lofas is not happy?
Lofas you don’t know what is going on inside Scancell. There may be some very high level discussions going on that hinge on the quality of the trial data due in 3 to 4 months time,
The market is not the truth it’s just sentiment in a vacuum.
I hoped that at least one new deal would have been confirmed by now but I don’t know what is happening or if anyone is seriously evaluating either AvidiMab or one of our GlyMab’s.
It’s just guess work at best. I would like to believe that the trials are building solid data that cannot be ignored. I would hope that both our Mab platforms are being well received and proving they do what it says on the tin.
So as I said before it’s up to us to decide if we hold on or take a hit and move on.
I’m holding on because everything trial wise is so far, looking very positive.
Not adding any more even at 0.1p, abysmal company shameful management , hope for good results for patient all be it not from this poke in the eye company.